Daratumumab: no evidence of disease after treatment?
Understanding the complexity of acute myeloid leukemia (AML)
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
The power of venetoclax
Mimetics: the future of AML treatment?